News

New Committee Positions Open

TOGA is opening nominations for key positions within the Scientific Committee, as well as inviting expressions of interest for our newly formed Preventative and Quality Healthcare Working Group, and two vital new subcommittees: Membership Engagement and Education.

Read on to find out how you can strengthen your CV, expand your network, learn about the process of peer-to-peer reviews, and contribute to TOGA’s strategic direction.

Scientific Committee Positions

The Scientific Committee is now accepting nominations from the membership for the following positions. These positions have either had terms concluded or are newly created.

The positions open for nominations are: 

  • Deputy Chair of the Scientific Committee (new role) 
  • Translational Research co-chair 
  • Preventative and Quality Healthcare co-chair (new role) 
  • Surgical Representative (new role) 

 Benefits of involvement in the Scientific Committee:

  • Play a role in guiding the research priorities of TOGA 
  • Secure a travel grant (if held outside home state) and free registration for ASM attendance 
  • Strengthen your professional network across thoracic oncology 
  • Strengthen your CV, especially for future grants, promotions, or leadership roles  
  • Guide early-career investigators and contribute to the development of future research leaders 
  • Help ensure trials reflect clinical priorities, feasibility, and unmet needs in thoracic oncology 
  • Invitation to TOGA ThinkTank event to identify and develop new concept opportunities 

If you are interested in nominating for one or more of these positions, please submit your interest through the Scientific Committee nomination formby 30 January 2026.  

Each nomination must be supported by one (1) current TOGA members. If you’ve been asked to support a nomination, please use the online support form to register your endorsement. 

Please read Scientific Committee Position Descriptions and Terms of Reference. 

New Working Group: Preventative and Quality Healthcare 

The Preventative and Quality Healthcare Working Group is newly established to review and advance research concepts in areas such as lung cancer screening, biomarker discovery, early intervention strategies, epidemiology, and quality-of-care research. 

If you are interested in joining the new Preventative and Quality Healthcare as a member, please express your interest here. We expect the first Working Group meeting to take over around April 2026. 

Working Group Terms of Reference can be found here

Two New Committees

TOGA is creating two new committees: the Membership Engagement Committee and the Education Committee.  

Membership Engagement Committee

The Membership Engagement Subcommittee works with TOGA staff to strengthen engagement with TOGA’s membership base and ensure members remain active, connected, and involved in TOGA’s mission. The Committee provides advice on strategies that foster volunteer contribution, enhance membership value, and support the long-term sustainability of the organisation. 

Education Committee

The Education Subcommittee works with TOGA staff to develop and deliver TOGA’s education program, including podcasts, webinars, workshops, website blogs, and other clinician-focused activities (excluding the Annual Scientific Meeting). They ensure TOGA’s educational activities are relevant, high-quality, and aligned with the organisation’s Strategic Plan and brand. 

Expectations

  • Meetings: typically 1 hour by video conference at least twice per year, with additional meetings scheduled as needed. 
  • Members will contribute to assigned tasks between meetings, for example reviewing membership data, advising on engagement initiatives, or contributing to communication strategies. 
  • Members are expected to review meeting materials prior to meetings and contribute constructively to agenda discussions. 

Appointments are voluntary and for a two-year term, renewable for up to three consecutive terms. TOGA typically supports committee members with travel grants to attend the TOGA ASM. 

Committee Position Descriptions can be found here

Share this

Facebook
Twitter
LinkedIn
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
New evidence is changing the way surgeons approach early-stage lung cancer, with lung-sparing surgery becoming an option for carefully selected patients.
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.
A re-cap of the Scientific Committee meeting in August 2025 and the year to date.
Celebrating TOGA's leadership transition: We honour the service of our past Board members and welcome the new Chair and Directors who will chart TOGA’s future.